IPH5201
Based on 1 Customer Validation
IPH5201 is a selective CD39 inhibitor and a humanized IgG1 monoclonal antibody. IPH5201 selectively binds to and inhibits the enzymatic activity of both membrane-bound and soluble CD39, blocking ATP hydrolysis. IPH5201 enhances the phenotypic maturation and activation of dendritic cells and macrophages. IPH5201 potentiates the anti-tumor effect of Oxaliplatin (HY-17371). IPH5201 shows preliminary evidence of disease stabilization in advanced solid tumor models when used as a single agent or in combination with Durvalumab (HY-P9919). IPH5201 can be used for the research of advanced solid tumors.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.24%
- 分子量:145.12 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
ENTPD1/CD39
体外実験
IPH5201 enhances phenotypic maturation and activation of dendritic cells and macrophages, and restores ATP-suppressed T-cell proliferation in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1X106 THP-1 cells labeling CD39 with IPH5201 (HY-P991444, red). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF488-conjugated Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control.
化学情報
-
性状 Liquid
-
分子量 145.12 kDa
-
Color Colorless to light yellow
-
SMILES
I[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5]
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Monocyte-derived dendritic cell differentiation
Human monocyte-derived dendritic cells are generated by isolating PBMC-derived monocytes and culturing them with GM-CSF plus IL-4, which produces cells with dendritic-cell antigen-presenting properties, reduced monocyte phenotype, and increased dendritic-cell functional readouts such as antigen uptake, allogeneic T-cell stimulation, and expression of markers including HLA-DR, CD80, CD86, CD83, CD1a, or CD209 depending on protocol and maturation state. The main readout is phenotypic and functional differentiation: immature MoDCs are commonly evaluated by loss or reduction of CD14 with acquisition of dendritic-cell markers and antigen uptake capacity, whereas mature MoDCs are evaluated by increased CD83, CD80, CD86, HLA-DR, and T-cell stimulatory function after exposure to maturation stimuli such as TNF-α or a cytokine/PGE2 cocktail.
純度とドキュメンテーション
-
データシート (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
IPH5201 関連分類
HY-P991444 関連分類
Powered by Bioz